Form 4: Fulgent Genetics CSO Sells Shares for Tax Obligations

Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, sold 535 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported a sale of common stock.
• The transaction involved the disposition of 535 shares of common stock on November 24, 2025.
• The shares were sold at a weighted-average price of $30.473 per share, with individual sales ranging from $30.33 to $30.62.
• The purpose of the sale was to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs).
• These RSUs were originally granted to Mr. Gao on February 23, 2023.
• Following this transaction, Mr. Gao beneficially owns 954,908 shares of Fulgent Genetics common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-planned contract, instruction, or written plan.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary sale of shares by an insider to cover tax obligations related to RSU vesting. This type of transaction is neutral and does not reflect positive or negative sentiment about the company's prospects.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction related to compensation and tax obligations, and it does not provide specific insights into broader industry trends or competitive positioning for Fulgent Genetics.

Stakeholder Impact

• Shareholders: The sale of a small number of shares for tax purposes by an executive is a routine event and is unlikely to have a material impact on the company's stock price or long-term shareholder value.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of a small number of shares by the Chief Scientific Officer to cover tax withholding obligations from RSU vesting. Such a transaction, especially when conducted under a Rule 10b5-1 plan, does not typically signal a change in management's confidence or the company's fundamentals. Therefore, it provides no new information that would warrant a change in an existing investment recommendation; a 'hold' stance is appropriate based solely on this filing.

Keywords

Fulgent Genetics, FLGT, Insider Transaction, Form 4, Stock Sale, RSU Vesting, Tax Withholding, Hanlin Gao, Chief Scientific Officer